Early Botulinum Toxin Type A Injection May Improve Motor Recovery in Patients with Post-Stroke Spasticity: A...

Area of Science:

• Neurology
• Rehabilitation Medicine
• Pharmacology

Background:

• Post-stroke spasticity significantly hinders motor control, recovery, and quality of life.
• Botulinum toxin type A is a primary treatment, but its efficacy may be limited by late administration during the chronic phase.
• Early intervention with botulinum toxin type A shows potential for enhanced rehabilitation, but functional benefits require further investigation.

Purpose of the Study:

• To investigate the impact of timing for the first botulinum toxin type A injection on outcomes in treatment-naïve post-stroke patients.
• To compare the effects of early (<90 days) versus late treatment on spasticity, motor function, and disability.

Main Methods:

• Secondary analysis of a multicenter, open-label, longitudinal cohort study.
• Participants received botulinum toxin type A injections combined with conventional rehabilitation.
• Outcome assessments included muscle tone, motor strength, sensorimotor recovery, and global disability at baseline and 4, 12, and 24 weeks post-injection.

Main Results:

• Patients treated within 90 days of stroke onset exhibited greater spasticity reduction at 4 and 12 weeks compared to later treatment groups.
• Early treatment led to faster and more significant improvements in upper-limb strength, sensorimotor recovery, and global disability, even with more severe baseline impairments.
• Statistical analyses revealed significant differences favoring early intervention.

Conclusions:

• Early administration of botulinum toxin type A is associated with improved spasticity reduction and enhanced motor recovery post-stroke.
• The benefits of early treatment are particularly pronounced in patients with severe initial neurological deficits.
• Timing of botulinum toxin type A intervention is a critical factor influencing rehabilitation outcomes in stroke survivors.